CHU de Liège
Tinlot, Liège, 4557, Belgium
NCT Number: NCT06817837
This controlled and randomized study aims to explore the feasibility and benefits of hypnosis in the management of patients who have suffered a traumatic brain injury or a stroke, by assessing its impact on behavioral disorders related to the dysexecutive syndrome, as well as associated symptoms (anxiety, sleep disorders, and pain).
For this study, a convenience sample of 40 adult patients with acquired brain injuries will be recruited and randomly assigned to two groups: one group will receive hypnosis sessions integrated into their usual care, and the control group will receive only conventional treatment. These patients are currently being followed in neurological rehabilitation with complaints (anxiety, sleep, pain, and/or behavioral disorders). These complaints will be initially assessed using visual analog scales (VAS) for these four points. Patients with scores higher than 4 on at least two of the scales will be admitted to the study. They will be randomly assigned to either the control or experimental group.
Sociodemographic data (age, sex, education) and certain medical data related to the brain injury will be collected, such as: the initial Glasgow Coma Scale score, medication treatment, lesion type, and the timing of the injury.
Several questionnaires and scales will be completed at patient inclusion and at the end of the protocol. The severity of behavioral disorders will be assessed using the DysEXecutive (DEX) questionnaire from the Behavioral Assessment of the Dysexecutive Syndrome (BADS). For anxiety, pain, and/or sleep disorders, the following questionnaires will be used: the State-Trait Anxiety Inventory (STAI), the Beck Depression Inventory, the Pittsburgh Sleep Quality Index (PSQI), and the Medical Outcome Study Short Form (SF-36) for quality of life.
For the hypnosis protocol (experimental group), 8 individual sessions will be offered to the patient, each lasting about one hour and spread over a period of 4 months (one hypnosis session every two weeks). The sessions will proceed as follows:
* In the first session, a history will be taken to gather the patient's request or issue for which they were referred for hypnosis, and specific goals will be established. An explanation of hypnosis will also be provided. * The second session will offer a "safe haven" hypnosis, where the patient revisits a happy moment to find calm and a secure place. * In the third session, a "red balloon" hypnosis will be offered, using a metaphor where the patient releases bothersome emotions. * The fourth session will focus on sleep (hypnotic metaphor for sleep induction). * The fifth session will use "object-tool" hypnosis, where the patient works on a specific issue represented metaphorically by an object and enhances it with tools that can modify it. * The sixth session will introduce self-hypnosis training for the patient. * The final two sessions will be personalized and address the patient's current needs.
At the end of each session, patients will be asked to complete a visual analog scale (VAS) to measure their level of absorption in the hypnosis.
Note that, except for the first two sessions, the order of the sessions may be slightly adjusted based on the patient's needs or requests. Patients in the control group will also complete the same questionnaires at inclusion and after 4 months.
During the 4-month period, all patients, from both the hypnosis and control groups, will continue to receive multidisciplinary rehabilitation care. Furthermore, the hypnosis sessions will replace one neuropsychology session each time so that both groups (control vs. hypnosis) receive the same number of sessions over the period. Finally, data will be analyzed for patients who have completed at least 80% of the prescribed hypnosis sessions.
Interested in participating?
Request Info18 year and older
All sexes
Interventional
Not applicable
Tinlot, Liège, 4557, Belgium
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Eight hypnosis sessions will be offered to address various issues: sleep disorders, behavioral issues, anxiety, and pain.
Time frame: At the inclusion of the patient and up to 8 weeks
This is a self-reported questionnaire designed to assess health-related quality of life. It includes 36 items distributed across 8 dimensions: physical function, physical role limitations, bodily pain, general health, vitality, social function, emotional role limitations, and mental health. Each dimension is scored on a scale from 0 to 100, where 0 represents the worst health status and 100 the best. The SF-36 allows for the calculation of two overall scores: one for physical health and another for mental health.
Time frame: At the inclusion of the patient and up to 8 weeks.
This scale consists of a 10 cm horizontal line, marked at both ends with descriptors such as "not at all" (0) to "completely" (10). Participants are asked to rate their feelings from 0 to 10 regarding four symptoms: "I feel anxious," "I have sleep disturbances," "I have disabling pain," and "I exhibit behavioral disturbances."
Time frame: At the inclusion of the patient and up to 8 weeks
Anxiety will be evaluated using the State-Trait Anxiety Inventory (STAI). The STAI is a psychometric tool that measures two aspects of anxiety: state anxiety (temporary anxiety related to a specific situation) and trait anxiety (stable, dispositional anxiety). It consists of two subscales, each with 20 items, rated from 1 (not at all) to 4 (very much). The total score for each subscale ranges from 20 to 80, with higher scores indicating higher levels of anxiety.
Time frame: At the inclusion of the patient and up to 8 weeks
The severity of behavioral disorders will be assessed using the DEX questionnaire from the Behavioural Assessment of the Dysexecutive Syndrome (BADS). This questionnaire was developed to evaluate executive dysfunction in daily life activities. It is a self-assessment measure consisting of 20 items that assess four dysexecutive criteria: behavioral, cognitive, motivational, and emotional changes, compared to premorbid functioning. Each item is rated on a 5-point Likert scale ranging from "never" to "very often." The sum of each item provides an overall score from 0 to 80. The higher the score, the more severe the executive disorders are. This questionnaire has the advantage of providing both a self-assessment from the patient and an external assessment by the patient's referring neuropsychologist.
Time frame: At the inclusion of the patient and at up to 8 weeks
This questionnaire is a self-reported tool consisting of 21 items, each rated from 0 to 3, assessing various symptoms of depression such as mood, cognition, sleep, and appetite. The total score ranges from 0 to 63, with thresholds indicating the severity of depression: 0-13 (minimal depression), 14-19 (mild), 20-28 (moderate), and 29-63 (severe). The scale is commonly used in both clinical practice and research to track the progression of depressive symptoms and measure the effectiveness of treatments.
Time frame: At the inclusion of the patient and up to 8 weeks
This self-reported questionnaire is designed to assess sleep quality and its impact on health over a 1-month period. It measures 7 components of sleep: subjective quality, sleep onset latency, sleep duration, usual sleep efficiency, sleep disturbances, use of sleep medication, and daytime dysfunction. Each component is rated from 0 to 3, with a total score ranging from 0 to 21. A score higher than 5 indicates poor sleep quality.
Time frame: At the inclusion of the patient
The MoCA is a cognitive assessment designed as a quick screening tool for detecting mild cognitive impairment. The MoCA evaluates the following cognitive domains: attention and concentration, executive functions, memory, language, visuoconstructive skills, conceptual thinking, calculations, and spatiotemporal orientation. This scale provides a total score out of 30, which is the sum of the different scores obtained in the sub-scores. With a threshold score of 26, a total score of 26 or higher is considered a normal score. A score below 26 indicates mild cognitive deficits. Investigators choose this scale both for its ease and speed of administration and for its sensitivity to even mild cognitive impairments.
Time frame: At the inclusion of patient
The GCS is an assessment scale for evaluating the level of consciousness. This scale is a structured evaluation based on 3 components, measured independently: eye opening (E), verbal response (V), and motor response (M). Each sub-scale has a number of grades, starting with the most severe score. Specifically, the "eye opening (E)" sub-scale ranges from 1 (no eye opening) to 4 points (spontaneous eye opening). The "verbal response (V)" sub-scale ranges from 1 (no verbal response) to 5 points (oriented response). Finally, the "motor response (M)" sub-scale ranges from 1 (no motor response) to 6 points (obeys commands). These 3 sub-scales give a total score between 3 (minimum possible score) and 15 (maximum possible score). Regarding interpretation, a score of 15 indicates a normal state. A score between 14 and 10 indicates drowsiness or light coma, while a score between 9 and 4 indicates an increasingly deep coma or unconsciousness. Finally, a score of 3 corresponds to a very deep coma.
Centre Hospitalier Universitaire de Liege
Other
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06782464
Autoimmune Diseases, Autoimmune Diseases of the Nervous System
Luxembourg
View Trial DetailsNCT07521384
Alzheimer Dementia (AD), Alzheimer Disease
Monterrey, Nuevo León, Mexico
View Trial DetailsNCT06973018
Autoimmune Diseases, Autoimmune Diseases of the Nervous System
Stockholm, Stockholm County, Sweden
View Trial DetailsNCT05277519
Brain Diseases, Brain Injuries
Paris, France
View Trial Details